Beta-Adrenergic Inhibition with Atenolol in Hypertensive Patients
نویسنده
چکیده
Early systemic hemodynamic adjustments to antihypertensire therapy with the cardioselective beta inhibitor, atenolol, were investigated in 12 hospitalized men, mean age 52 years, with uncomplicated mildto-moderate essential hypertension. Twice daily measurements of cardiac output (CO) by CO3 rebreathing, blood pressure by cuff, and heart rate were performed in all subjects for 3 days before and S days after initiation of oral atenolol therapy (50 or 100 mg daily). Cardiac output by CO, rebreathing was checked with dye diluion just before, and 4 hours and 4 days after the start of therapy. Plasma volume (radioiodinated albumin) was measured before therapy and on Day 5 of therapy. The CO results obtained with the two methods were not significantly different (r = 0.88,p < 0.01, n = 12). A reduction in heart rate, 18 ± 2 beats/min (mean ± SE), occurred in all patients while taking atenolol. By 4 hours after the first dose of atenolol, CO fell from 5.49 ± 030 to 4.24 ± 0.21 liters/min (p < 0.01), while the control mean arterial pressure (MAP) of 108 ± 4 mm Hg was not significantly changed, 110 ± 4 mm Hg. At 24 hours, CO returned near baseline (5.10 ± 0.21 liters/min) but MAP was reduced (95 ± 3 mm Hg, p < 0.001) and remained so thereafter. CO remained at baseline at 48 hours (5.50 ± 0.29 liters/min) but fell again (p < 0.01) to 4.81 ± 0.11 on Day 4 and to 4.68 ± 0.25 liters/min on Day 5 of atenolol therapy. Plasma volume, 3110 ± 100 ml before therapy, was reduced to 2850 ± 100 by Day 5 of atenolol therapy (p < 0.01). The findings indicate a delayed onset of the antihypertensive action of atenolol. The transient return to baseline of CO on Day 2 and 3 of atenolol therapy suggests a reverse autoregulatory adjustment to the initial fall in CO. (Hypertension 3: 262-268, 1981)
منابع مشابه
Does atenolol differ from other β-adrenergic blockers?
BACKGROUND A recent meta-analysis of drug effects in patients with hypertension claims that all beta-adrenergic blockers are equally effective but less so than other antihypertensive drugs. Published comparisons of the beta-adrenergic blocker atenolol and non-atenolol beta-adrenergic blockers indicate different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis po...
متن کاملClinical evaluation of atenolol in hypertensive patients.
Atenolol, a cardioselective beta-adrenergic blocking agent, was given as the sole hypotensive drug for 8-12 weeks to 20 patients with hypertension of varying degrees of severity. Initial systolic blood pressure ranged from 162-238 mm Hg (mean +/- SEM 196 +/- 5.5 mm Hg) and diastolic blood pressure ranged from 105-143 mm Hg (118 +/- 2.5 mm Hg). Three patients had accelerated hypertension, six ha...
متن کاملBeta-blockers Are Not a Good Initial Choice for Hypertension: True or False?
• In most of the RCTs analyzed by these investigators, atenolol was the beta-blocker used for comparison. Worldwide, atenolol is one of the most prescribed beta-blockers. • Their analysis indeed suggests that atenolol does not give hypertensive patients adequate protection against cardiovascular disease (CVD). These investigators failed to recognize that beta-blockers possess important and subt...
متن کاملControlled study of atenolol in treatment of hypertension.
The antihypertensive effect of atenolol, a new beta-1-receptor blocking agent, was studied in a double-blind trial in which 45 patients with essential hypertension were randomly assigned to placebo or atenolol treatment. Atenolol caused a statistically significant and clinically relevant reduction of blood pressure. The optimum daily dose for moderately severe hypertension was considered to be ...
متن کاملAtenolol and bendrofluazide in hypertension.
The effect of atenolol, a new beta-1-adrenergic receptor blocking agent, was studied in a double-blind cross-over trial in 24 carefully selected hypertensive outpatients. After a four-week run-in period on matching placebo each patient received atenolol 200 mg/day, atenolol 400 mg/day, a combination of atenolol 200/mg day with bendrofluazide 5 mg/day, and bendrofluazide 5 mg/day alone, accordin...
متن کاملHypertension in hypoglycemic diabetics treated with beta-adrenergic antagonists.
To evaluate the response during insulin-induced hypoglycemia, diabetics treated with relatively selective or nonselective beta-adrenergic blocking agents were studied. Placebo, atenolol (100 mg/day), and propranolol (80 mg b.i.d.) were administered to 12 insulin-treated diabetics for 1 week in a double-blind, randomized, crossover fashion with a 2-week washout between treatments. Sufficient int...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005